Working... Menu

A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01164696
Recruitment Status : Completed
First Posted : July 19, 2010
Last Update Posted : August 24, 2010
Information provided by:

Brief Summary:
The objective of this study is to compare hematological toxicity, costs, health-related quality of Life (HR-QOL) and outcomes observed in real life in the Belgian Non-Hodgkin Lymphoma (NHL) population receiving 90Y-Zevalin, with model-predicted data at reimbursement on the basis of a clinical trial in heavily pre-treated NHL.

Condition or disease Intervention/treatment
Lymphoma, Follicular Non-Hodgkin Lymphoma Drug: [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)

Layout table for study information
Study Type : Observational
Actual Enrollment : 30 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Prospective Observational Study to Evaluate Quality of Life and Costs in a Real Life Setting in Patients Treated With 90Y-Zevalin
Study Start Date : August 2007
Actual Primary Completion Date : May 2009
Actual Study Completion Date : May 2009

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Group 1 Drug: [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)
Zevalin was administered according to the directives in the approved package leaflet.

Primary Outcome Measures :
  1. The medical resources consumed due to hematological adverse events that occurred following treatment with 90Y-Zevalin treatment [ Time Frame: one year after inclusion ]

Secondary Outcome Measures :
  1. the health related quality of life prior to and following treatment (using EQ-5D and FACT-LYM) [ Time Frame: baseline: before 1st administration, 8 days after baseline, 1, 2 & 3 months after baseline ]
  2. the clinical outcomes (survival status, response status), TTNT (time to next treatment) [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients with relapsed or refractory FL who have been treated with 90Y-Zevalin in Belgium within the first 24 months after ethics approval

Inclusion Criteria:

  • Advanced cancer of the lymph nodes of follicular type at study inclusion
  • The patient has relapsed or has refractory disease, after previous treatment with rituximab
  • Treating physician has decided to treat the patient with a 90Y-Zevalin regimen
  • The patient is >= 18 years of age
  • Patient has given informed consent

Exclusion Criteria:

  • Patient is unwilling or unable to give informed consent
  • Patient is participating in another clinical trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01164696

Layout table for location information
Many Locations, Belgium
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer

Layout table for additonal information
Responsible Party: Medical Director, Bayer Schering Pharma AG Identifier: NCT01164696     History of Changes
Other Study ID Numbers: 13455
First Posted: July 19, 2010    Key Record Dates
Last Update Posted: August 24, 2010
Last Verified: August 2010

Keywords provided by Bayer:
Quality of Life, Health Care Costs

Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Non-Hodgkin
Lymphoma, Follicular
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs